

# Janice P Dutcher

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3481269/publications.pdf>

Version: 2024-02-01

97  
papers

11,760  
citations

136950

32  
h-index

48315

88  
g-index

101  
all docs

101  
docs citations

101  
times ranked

9867  
citing authors

#	ARTICLE	IF	CITATIONS
1	Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2007, 356, 2271-2281.	27.0	3,490
2	High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993. <i>Journal of Clinical Oncology</i> , 1999, 17, 2105-2105.	1.6	1,810
3	Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 909-918.	1.6	948
4	Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 133-141.	1.6	746
5	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN) Tj ETQq1 1 0.784314 ggBT /Overlock 10 13.7 529	1.6	529
6	Seeking meaning and hope: self-reported spiritual and existential needs among an ethnically-diverse cancer patient population. <i>Psycho-Oncology</i> , 1999, 8, 378-385.	2.3	344
7	Evolving Strategies for the Management of Handâ€œFoot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib. <i>Oncologist</i> , 2008, 13, 1001-1011.	3.7	315
8	Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 3133-3140.	1.6	307
9	Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. <i>Cancer</i> , 2010, 116, 1272-1280.	4.1	240
10	Effect of temsirolimus versus interferon-Î± on outcome of patients with advanced renal cell carcinoma of different tumor histologies. <i>Medical Oncology</i> , 2009, 26, 202-209.	2.5	239
11	Phase I Study of Recombinant Human CD40 Ligand in Cancer Patients. <i>Journal of Clinical Oncology</i> , 2001, 19, 3280-3287.	1.6	209
12	Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. <i>Blood</i> , 2001, 97, 1514-1516.	1.4	180
13	Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. <i>Cancer</i> , 2004, 101, 1545-1551.	4.1	163
14	The High-Dose Aldesleukin â€œSelectâ€•Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 561-568.	7.0	133
15	High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014. , 2014, 2, 26.		130
16	Cytoreductive Surgery for Stage IV Renal Cell Carcinoma. <i>Journal of Urology</i> , 1995, 154, 32-34.	0.4	116
17	A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. <i>Medical Oncology</i> , 2012, 29, 761-767.	2.5	105
18	Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. , 2019, 7, 49.		102

#	ARTICLE	IF	CITATIONS
19	Mammalian Target of Rapamycin Inhibition. <i>Clinical Cancer Research</i> , 2004, 10, 6382S-6387S.	7.0	90
20	Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1533-1544.	4.2	89
21	Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation. <i>Journal of Clinical Oncology</i> , 2019, 37, 2062-2071.	1.6	80
22	Introduction: History of the management of advanced renal cell cancer. <i>Medical Oncology</i> , 2009, 26, 1-2.	2.5	75
23	Platelet Activation Induced by Interleukin-6: Evidence for a Mechanism Involving Arachidonic Acid Metabolism. <i>Thrombosis and Haemostasis</i> , 1994, 72, 302-308.	3.4	73
24	Recent developments in the treatment of renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2013, 5, 338-353.	2.0	64
25	Phase II Studies of Recombinant Human Interleukin-4 in Advanced Renal Cancer and Malignant Melanoma. <i>Journal of Immunotherapy</i> , 1994, 15, 147-153.	2.4	58
26	Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha. <i>Cancer</i> , 1991, 68, 1538-1544.	4.1	56
27	Disseminated strongyloidiasis with central nervous system involvement diagnosed antemortem in a patient with acquired immunodeficiency syndrome and Burkitts lymphoma. <i>Cancer</i> , 1990, 66, 2417-2420.	4.1	52
28	Clinical Trial Experience With Temsirolimus in Patients With Advanced Renal Cell Carcinoma. <i>Seminars in Oncology</i> , 2009, 36, S26-S36.	2.2	51
29	Granulocyte transfusion therapy and amphotericin B: Adverse reactions?. <i>American Journal of Hematology</i> , 1989, 31, 102-108.	4.1	50
30	Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. <i>Medical Oncology</i> , 2011, 28, 1530-1533.	2.5	47
31	Renal parenchymal tumors and lymphoma in the same patient: Case series and review of the literature. <i>American Journal of Hematology</i> , 2006, 81, 271-280.	4.1	44
32	Mammalian target of rapamycin (mTOR) inhibitors. <i>Current Oncology Reports</i> , 2004, 6, 111-115.	4.0	42
33	Adenocarcinoma arising in vulvar breast tissue. <i>Cancer</i> , 1988, 62, 2234-2238.	4.1	41
34	Kidney Cancer: The Cytokine Working Group Experience (1986 -2001): Part II: Management of IL-2 Toxicity and Studies with Other Cytokines. <i>Medical Oncology</i> , 2001, 18, 209-220.	2.5	40
35	Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry. , 2019, 7, 84.		34
36	Morphologic and ultrastructural evidence for interleukin-6 induced platelet activation. <i>American Journal of Hematology</i> , 1995, 48, 92-99.	4.1	33

#	ARTICLE	IF	CITATIONS
37	Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM SM. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 31-41.e4.	1.9	31
38	Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. , 2017, 5, 102.		31
39	Association of thyroid disease with acute leukemia. <i>American Journal of Hematology</i> , 1992, 39, 102-107.	4.1	28
40	Adhesive receptors expressed by tumor cells and platelets: novel targets for therapeutic anti-metastatic strategies. <i>Medical Oncology</i> , 1995, 12, 95-102.	2.5	28
41	Kidney Cancer: The Cytokine Working Group Experience (1986 -2001): Part I. IL-2-Based Clinical Trials. <i>Medical Oncology</i> , 2001, 18, 197-208.	2.5	27
42	Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy. <i>Cancer</i> , 2005, 104, 2392-2399.	4.1	27
43	Blastic phase of chronic myelogenous leukemia. <i>Current Treatment Options in Oncology</i> , 2006, 7, 189-199.	3.0	27
44	A Phase II Study of Bevacizumab and High-dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Immunotherapy</i> , 2013, 36, 490-495.	2.4	25
45	20th Century Advances in Drug Therapy in Oncology Part I. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 1007-1024.	2.0	22
46	Effects of interleukin-2 administration on platelet function in cancer patients. <i>American Journal of Hematology</i> , 1994, 45, 224-231.	4.1	20
47	A Phase II Study of the Continuous Intravenous Infusion of Interleukin-6 for Metastatic Renal Cell Carcinoma. <i>Journal of Immunotherapy</i> , 1995, 18, 52-56.	2.4	19
48	Impact of histology on the treatment outcome of metastatic or recurrent renal cell carcinoma. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1998, 15, 44-49.	1.1	19
49	Novel Management of Pruritus in Patients Treated With IL-2 for Metastatic Renal Cell Carcinoma and Malignant Melanoma. <i>Journal of Immunotherapy</i> , 2010, 33, 1010-1013.	2.4	19
50	Polyethylene glycolated interleukin-2 as maintenance therapy for acute myelogenous leukemia in second remission. <i>American Journal of Hematology</i> , 1994, 47, 41-44.	4.1	17
51	Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. <i>Targeted Oncology</i> , 2016, 11, 229-234.	3.6	17
52	A distinct coagulopathy associated with Interleukin-2 therapy. <i>British Journal of Haematology</i> , 1994, 88, 892-894.	2.5	16
53	On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment Cytokines, Targeted Therapy, and Immunotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 418-435.	3.8	16
54	Stratification by Risk Factors Predicts Survival on the Active Treatment Arm in a Randomized Phase II Study of Interferon-Gamma Plus/Minus Interferon-Alpha in Advanced Renal Cell Carcinoma (E6890). <i>Medical Oncology</i> , 2003, 20, 271-282.	2.5	15

#	ARTICLE	IF	CITATIONS
55	Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 6098-6106.	7.0	14
56	Experience with sorafenib and the elderly patient. <i>Medical Oncology</i> , 2010, 27, 1359-1370.	2.5	13
57	Effect of histocompatibility factors on pulmonary retention of indium-111-labeled granulocytes. <i>American Journal of Hematology</i> , 1990, 33, 238-243.	4.1	12
58	Update on the Biology and Management of Renal Cell Carcinoma. <i>Journal of Investigative Medicine</i> , 2019, 67, 1-10.	1.6	12
59	<i>Clostridium cadaveris</i> bacteremia in the immunocompromised host. <i>Medical and Pediatric Oncology</i> , 1993, 21, 70-72.	1.0	11
60	Effect of retinoic acid and interferon alpha on granulocyte-macrophage colony forming cells in chronic myeloid leukemia: Increased inhibition by all-trans- and 13-cis-retinoic acids in advanced stage disease. <i>Leukemia Research</i> , 1994, 18, 741-748.	0.8	11
61	Angiogenesis and melanoma. <i>Current Oncology Reports</i> , 2001, 3, 353-358.	4.0	11
62	Association between age and sex and mortality after adjuvant therapy for renal cancer. <i>Cancer</i> , 2019, 125, 1637-1644.	4.1	11
63	Phase II trial of merbarone in patients with malignant brain tumors. <i>Medical Oncology</i> , 1997, 14, 159-162.	2.5	10
64	Long-Term Progression-Free Survival of Patients with Metastatic Melanoma or Renal Cell Carcinoma following High-Dose Interleukin-2. <i>Journal of Investigative Medicine</i> , 2021, 69, 888-892.	1.6	10
65	Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800). <i>Clinical Genitourinary Cancer</i> , 2015, 13, 531-539.e1.	1.9	9
66	Alterations in Platelet Function in Patients Receiving Interleukin-6 as Cytokine Therapy. <i>Cancer Investigation</i> , 1996, 14, 307-316.	1.3	8
67	Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: A study of the Eastern Cooperative Oncology Group (E1993). <i>Leukemia and Lymphoma</i> , 2005, 46, 377-385.	1.3	8
68	Interleukin-2 Based Therapy for Kidney Cancer. <i>Cancer Treatment and Research</i> , 2003, 116, 155-172.	0.5	8
69	Porphyria cutanea tarda in a patient with acute leukemia. <i>American Journal of Hematology</i> , 1986, 23, 69-75.	4.1	6
70	The role of Epstein-Barr virus and elevated levels of tumor necrosis factor in determining prognosis in Asian peripheral T-cell lymphomas. <i>Leukemia Research</i> , 2003, 27, 467-469.	0.8	6
71	Pulmonary Langerhans cell histiocytosis, acute myeloid leukemia, and myelofibrosis in a large family and review of the literature. <i>Leukemia Research</i> , 2018, 67, 39-44.	0.8	6
72	Unique Dermatological Complication of rhM-CSF Treatment. <i>Leukemia and Lymphoma</i> , 1994, 15, 347-349.	1.3	5

#	ARTICLE	IF	CITATIONS
73	Objective Response of Multiple Myeloma to Cyclosporin A. <i>Leukemia and Lymphoma</i> , 1994, 16, 167-170.	1.3	5
74	A Review of Evidence-Based Treatment of Stage IIB to Stage IV Melanoma. <i>Cancer Investigation</i> , 2005, 23, 323-337.	1.3	5
75	Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805). <i>Clinical Cancer Research</i> , 2021, 27, 3397-3403.	7.0	5
76	Long-term (LT) disease-free survival (DFS) of melanoma (MM) and renal cell cancer (RCC) patients following high-dose interleukin-2 (HD IL2).. <i>Journal of Clinical Oncology</i> , 2017, 35, e21005-e21005.	1.6	5
77	An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). Eastern Cooperative Oncology Group. <i>Investigational New Drugs</i> , 1997, 15, 165-172.	2.6	4
78	A Phase 2 Study of Moderate Dose Interleukin-2 and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic or Unresectable Renal Cell Carcinoma. <i>Journal of Immunotherapy</i> , 2005, 28, 576-581.	2.4	4
79	Occurrence of renal cell carcinoma and hematologic malignancies (predominantly lymphoid) in individuals and in families. <i>Familial Cancer</i> , 2016, 15, 677-687.	1.9	4
80	High-dose interleukin-2 in metastatic disease: renal cell carcinoma and melanoma. <i>Oncology</i> , 2002, 16, 3.	0.5	4
81	Families with both Hodgkin lymphoma and multiple myeloma in their pedigrees. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 257-60.	0.3	4
82	Report of a Phase I Evaluation of Dose and Schedule of Interleukin-1 Alpha and Cyclophosphamide in Patients with Advanced Tumors: An Eastern Cooperative Oncology Group Study (PX990) and Review of IL-1-Based Studies of Hematopoietic Reconstitution. <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 376-384.	1.2	3
83	Renal cell carcinoma in patients with a personal or family history of hematologic malignancies. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 392-7.	0.3	3
84	A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia. <i>Medical Oncology</i> , 2010, 27, 728-735.	2.5	2
85	Interleukin-2 Can Cure Kidney Cancer. <i>Oncologist</i> , 2018, 23, e107-e107.	3.7	2
86	Management of hepatitis B in the era of checkpoint inhibition. , 2020, 8, e000276.		2
87	An Eastern Cooperative Oncology Group phase I trial of all-trans-retinoic acid and interferon-alpha: E2Y92. <i>Investigational New Drugs</i> , 1997, 15, 319-324.	2.6	1
88	Immunotherapy: are we making a difference?. <i>Current Opinion in Urology</i> , 2000, 10, 435-439.	1.8	1
89	Clinical impact of multidrug resistance in acute leukemia. <i>Leukemia Research</i> , 2002, 26, 323-325.	0.8	1
90	Steven C. Campbell, Brian I. Rini (eds): Renal cell carcinoma: Clinical management (Current clinical) Tj ETQq0 0 0 rgBT_/Overlock 10 Tf 50	2.5	1

#	ARTICLE	IF	CITATIONS
91	MP30-12 RENAL CELL CARCINOMA AND NON-HODGKINâ€™S LYMPHOMA: GENOMIC APPROACHES TO IDENTIFICATION OF SHARED SUSCEPTIBILITY. <i>Journal of Urology</i> , 2014, 191, .	0.4	1
92	Management of Patients with Pathologic Variants of Renal Cell Carcinoma: Papillary, Collecting Duct, Medullary and Chromophobe Carcinoma, and Sarcomatoid Differentiation. , 2008, , 529-544.		1
93	Association of Renal Cell Carcinoma and B-Cell Hematological Malignancy. <i>Blood</i> , 2012, 120, 5086-5086.	1.4	1
94	Association of renal cell carcinoma and hematologic malignancy.. <i>Journal of Clinical Oncology</i> , 2013, 31, 449-449.	1.6	1
95	Treating severe hemapheresis donor reactions. <i>Transfusion</i> , 1984, 24, 410-410.	1.6	0
96	â€œPseudoprogessionâ€ more than semantics. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1473-1474.	4.2	0
97	Gender effects in cancer treatment and outcome. <i>British Journal of Haematology</i> , 2021, 194, 229-230.	2.5	0